Faeth Therapeutics (FTH) Earnings Analysis

Faeth Therapeutics (FTH) has no confirmed upcoming earnings date. Last quarter (2026-05-15) it missed with EPS -131.45 USD vs -0.62 USD est (-21101.6%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -0.19.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does FTH next report earnings?

No confirmed upcoming earnings date is currently scheduled for FTH. This page updates as the calendar is published.

FTH earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-15-131.45 USD-0.62 USD-21101.6%Miss
2026-03-30-3.74 USD-4.81 USD+22.2%Beat
2025-11-14-3.62 USD-4.11 USD+11.9%Beat
2024-11-14-5.8 USD-6.2 USD+6.5%Beat

Beat rate: 3/4 (75%) over reported quarters with consensus data.

FTH valuation and analyst view

Trailing P/E-0.19
Trailing EPS-142.43289 USD
Price / book0.19
Dividend yield0.00%
Market cap0.04B
Analyst consensusBuy (4 buy / 0 hold / 0 sell)
Avg price target55.67 USD

Related research pages

Frequently asked questions

When is Faeth Therapeutics (FTH)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for FTH. This page updates as the calendar is published.

Did FTH beat earnings last quarter?

In its 2026-05-15 report, FTH posted EPS of -131.45 USD versus a -0.62 USD estimate — a miss of 21101.6%.

What is FTH's earnings track record?

Over the last 4 reported quarters with consensus data, FTH beat estimates 3 times (75%).

What is FTH's current P/E ratio and EPS?

FTH trades at a trailing P/E of -0.19 on trailing EPS of -142.43289072562337 USD.

What do analysts rate FTH?

Analyst consensus is "Buy" across 4 ratings (0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 55.67 USD.